



Therapeutic Effect of Bromocriptine as a Dopamine Agonist on Endometrioma Size: A Double-Blind Randomized Controlled Trial

Tahere Poordast¹, Marziyeh Parizad Nasir Kandi^{2*}, Elnaz Hosseini Najarkolaei², Elham Askari¹, Azizeh Farshbaf Khalili³

Abstract

Objectives: This study aimed to assess the therapeutic effect of a dopamine agonist (bromocriptine) together with medroxyprogesterone for three months on ovarian endometrioma size.

Materials and Methods: In this double-blind randomized clinical trial, 60 women with clinical or ultrasonographic evidence of residual ovarian endometriomas were randomly assigned into two groups (n=30/each): the Bromo group received medroxyprogesterone (20 mg) and bromocriptine (1.25 mg) twice a day orally for three months and the placebo group received medroxyprogesterone (20 mg) and placebo twice a day orally for three months. Demographic characteristics, pre- and post-treatment endometrioma size, pelvic pain, dysmenorrhea, and dyspareunia were compared in both groups.

Results: Mean endometrioma size was significantly different in both groups compared with the pre-treatment stage ($P < 0.0001$). Endometriosis symptoms of dysmenorrhea, dyspareunia, and pelvic pain improved after the treatment in Bromo group compared with placebo group ($P < 0.01$).

Conclusions: We found that medroxyprogesterone with placebo is effective in reducing the ovarian endometrioma size and also improves dysmenorrhea, dyspareunia, and pelvic pain, but the combination of medroxyprogesterone and bromocriptine has a stronger effect than using medroxyprogesterone alone.

Keywords: Ovarian endometrioma, Dysmenorrhea, Dyspareunia, Pelvic pain, Bromocriptine

Introduction

Endometriosis is a gynecological disorder characterized by the presence of endometrial tissue, including glands and stroma in extra-uterine sites, most commonly in the ovaries and peritoneum (1,2). Ovarian endometriomas occur in 17%-44% of women with endometriosis (3) and affect their quality of life, work efficiency, and sexual life (4). The most common symptoms of endometrioma are severe pelvic pain, dysmenorrhea, dyspareunia, and infertility (5). Endometrioma has multifactorial causes, including genetic, environmental, and hormonal (especially estrogen) factors and alteration in the immune system (6,7). Histological examinations have shown the presence of blood vessels and the vascularized area around the endometriotic lesions, suggesting that angiogenesis plays an essential role in the development and continuation of endometriotic lesions (8). In animal models of endometriosis, several antiangiogenic agents target the angiogenesis pathway, and they have been used successfully to disrupt the endometrial vasculature (9).

Dopamine receptor agonists have recently been studied to disrupt the blood supply to endometriosis lesions (10,11). The development, maintenance and progression

of endometriosis is due to various altered mechanisms including cell proliferation, immune function, apoptosis, and angiogenesis(12) The growing knowledge of the various molecular pathways involved in the development of endometriosis paves the way for the investigation of new drugs (13,14). So, the purpose of this study was to evaluate the effect of bromocriptine, as a dopamine agonist, on ovarian endometrioma size and its clinical symptoms.

Materials and Methods

Study Design and Participants

In this double-blind randomized clinical trial, 60 women with clinical or ultrasonographic evidence of residual ovarian endometriomas referred to the Ghadir Mother and Child Hospital, Shiraz, Iran from December 2020 to February 2021 were enrolled. The exclusion criteria were hyperprolactinemia, coagulation disorders, and having contraindications to medroxyprogesterone.

Interventions

The participants were randomly assigned into two groups: the Bromo group received 40 mg/day medroxyprogesterone (Abu Reihan Pharmacy, Iran) and

Received 8 February 2020, Accepted 21 August 2020, Available online 21 April 2022

¹Infertility Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ²Laparoscopy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ³Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.

*Corresponding Author: Marziyeh Prized Nasir Kandi, Tel: (+98) 9143469908, Email: parizad116@gmail.com



Key Messages

- ▶ Combination therapy with medroxyprogesterone and bromocriptine reduces ovarian endometrioma size.
- ▶ Combination of medroxyprogesterone and bromocriptine relief pain in women with endometrioma.
- ▶ The combination of medroxyprogesterone and bromocriptine has a better effect on the endometriosis symptoms than medroxyprogesterone alone.

1.25 mg of bromocriptine twice a day (Minoo Co. Iran), orally for three months and the placebo group received medroxyprogesterone (40 mg/d, orally) and the placebo (prepared by Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran) twice a day for three months.

Outcomes and Data Collection

Pre- and post-treatment assessments of endometrioma size were performed by ultrasonography. The impact of this treatment on pelvic pain, dysmenorrhea, and dyspareunia was assessed by using a visual analog scale (VAS), which was a 10 cm ruler with 11 grades as follows: 0 (no pain), 1-3 (mild pain), 4-7 (moderate pain), and 8-10 (severe) pain. This scale has adequate validity and reliability (12).

Sample Size

Due to the lack of the similar research, the sample size was estimated to be minimum of 60 (30 in each group) by considering $\alpha = 0.05$, power 80%, and acceptable difference, based on our pilot study

Randomization

To conceal the random allocation process, 60 treatment

cards were written in sequential order, then the cards were placed in sealed envelopes. On each envelope, a random code was written with no sequences that only the methodologist was aware of the code. When the physician announced a participants' eligibility, the methodologist provided the envelope. The person who evaluated the final outcomes was unaware of the random allocation process and the type of treatment performed. Data were analysed by a statistical expert who was separated from the study process and unaware of all the processes performed.

Data Analysis

All data were evaluated using descriptive statistics (i.e., mean, standard deviation, frequency, and percentage). The Student *t* test was used to compare the quantitative data. The normal distribution of data was assessed by the Kolmogorov-Smirnov and chi-square tests. Data were analyzed by the Statistical Package for the Social Sciences software (SPSS, version 20.0 for Windows; SPSS Inc., Chicago, IL). A *P* value of < 0.05 was considered statistically significant.

Results

Initially, 80 women were eligible to enter the study. Out of them, 20 women were excluded due to having coagulation disorders ($n = 6$) and hyperprolactinemia ($n = 6$), also declined to continue participating in the study ($n = 8$). Finally, a total of 60 women aged 18 to 45 years (median age 31 years) were assigned to two groups ($n=30$ /each), and their data were analyzed (Figure 1).

There were no statistically significant differences between the two groups in demographic characteristics, such as age, body mass index (BMI), gravidity, live birth rates, and endometrioma size (Table 1). The endometrioma size in the placebo and Bromo groups




Figure 1. The Consort Flow Chart of the Study.

was 54.4 ± 14.79 mm and 51.67 ± 13.75 mm, respectively. After the 3-month treatment, mean endometrioma size significantly decreased in the both group ($P < 0.0001$). Also, pelvic pain, dysmenorrhea, and dyspareunia significantly decreased compared with pre-treatment in two groups and in any of the participants, the score of 8-10 was not observed (Table 2). As well as, we did not find any significant differences between the two groups after treatment in the Endometrioma size and pain symptoms (Table 3).

Discussion

Ovarian endometriomas occur in 17%-44% of women with endometriosis. Studies have shown estrogen stimulates the growth of endometriosis and increases the risk of disease (15,16). On the other hand, studies have

reported that patients with endometriosis have high levels of angiogenic and proteolytic factors (17). Therefore, the pathogenesis and treatment of endometriosis is controversial and a challenge for the health care system (13,14). Some studies on endometriosis have examined the effect of medroxyprogesterone to partially or fully suppress estrogen (15,16) and dopamine agonists to inhibit angiogenesis (19-17). In this study, the effects of both medroxyprogesterone and bromocriptine on size and clinical symptoms of ovarian endometrioma were investigated. We found that medroxyprogesterone is effective for ovarian endometrioma, and the combination of medroxyprogesterone and bromocriptine has a stronger effect than the single medication. The results of this study showed that the mean endometrioma size was significantly different in both groups compared with

Table 1. Comparison of Demographic Characteristics between Two Study Groups (n=30/each)

Variables	Bromo Group	Placebo Group	P Value
Age (y), mean \pm SD	31.6 \pm 4.7	31.9 \pm 4.5	0.82 ^a
BMI (kg/m ²), mean \pm SD	25.1 \pm 3.4	25.1 \pm 2.5	0.98 ^a
Endometrioma size, mean \pm SD	54.40 \pm 14.7	51.76 \pm 13.7	0.47 ^a
Gravidity, No. (%)			
0	9 (30.0)	6 (20.0)	0.78 ^b
1	10 (33.3)	10 (33.3)	
2	7 (23.3)	8 (26.7)	
≥ 3	4 (13.3)	6 (20.0)	
Live birth, No. (%)			
0	9 (30.0)	6 (20.0)	0.61 ^b
1	10 (33.3)	10 (33.3)	
> 2	11 (36.7)	14 (46.7)	

^a Independent t test; ^b Chi-squared test.

Table 2. Comparison of the Endometrioma Size, Pelvic Pain, Dysmenorrhea, and Dyspareunia in Two Study Groups Before and After Treatment

Outcomes	Placebo Group (Before Treatment)	Placebo Group (After Treatment)	Bromo Group (Before Treatment)	Bromo Group (After Treatment)
Endometrioma size (mm), mean \pm SD	54.40 \pm 14.7	36.16 \pm 10.0	51.76 \pm 13.7	32.40 \pm 9.0
P value ^a		<0.001		<0.001
Pelvic Pain, No. (%)				
Absent	5 (16.7)	8 (26.7)	3 (10.0)	11 (36.7)
Mild (1-3)	5 (16.7)	15 (50.0)	5 (16.7)	16 (53.3)
Moderate (4-7)	13 (43.3)	7 (23.3)	18 (60.0)	3 (10.0)
Severe (8-10)	7 (23.3)	0 (0.0)	4 (13.3)	0 (0.0)
P value ^b		0.013		0.003
Dysmenorrhea, No. (%)				
Absent	0 (0.0)	3 (10.0)	0 (0.0)	4 (13.3)
Mild (1-3)	0 (0.0)	18 (60.0)	0 (0.0)	14 (46.7)
Moderate (4-7)	14 (46.7)	9 (30.0)	11 (36.7)	12 (40.0)
Severe (8-10)	16 (53.3)	0 (0.0)	19 (63.3)	0 (0.0)
P value ^b		0.014		0.01
Dyspareunia, No. (%)				
Absent	6 (20.0)	8 (26.7)	6 (20.0)	7 (23.3)
Mild (1-3)	3 (10.0)	14 (40.7)	1 (3.3)	13 (43.3)
Moderate (4-7)	11 (36.7)	8 (26.7)	10 (33.3)	10 (33.3)
Severe (8-10)	10 (33.3)	0 (0.0)	13 (43.3)	0 (0.0)
P value ^b		0.002		0.001

^a Paired t test; ^b Kappa test.

Table 3. Comparison of the Endometrioma Size and Pain Symptoms in Two Study Groups Before and After Treatment

	<i>P</i> Value ^a			
	Placebo Group (Before Treatment)	Bromo Group (Before Treatment)	Placebo Group (After Treatment)	Bromo group (After Treatment)
Endometrioma size		0.47		0.13
Pelvic pain		0.54		0.34
Dysmenorrhea		0.43		0.58
Dyspareunia		0.69		0.85

^a Chi-square test.

pre-treatment ($P < 0.001$) (Table 1). Also, we did not find any significant differences between the two groups after treatment in the Endometrioma size and pain symptoms (Table 3). Ercan and co-workers indicated that dopamine agonists are effective in the regression of endometriotic implants in rats, and after treatment, the endometriotic surface areas are significantly reduced. They also suggested that dopamine agonists are useful therapeutics, most likely by acting through a mechanism that reduces angiogenesis (9). Gómez and colleagues described a reduction in the size of human peritoneal endometriotic lesion by repeated laparoscopy of same patients after dopamine agonist administration (18). Other studies in a murine model, demonstrated that treatment with a dopamine agonist reduces the number of immature blood vessels and endometriosis-related nerve fiber and the size of the endometriotic (11,19,20). These findings are in line with our results. A study was carried out on the effect of cabergoline as a dopamine agonist on endometrioma size. They observed a significant decrease in 64.7% of subjects treated with cabergoline. The impact of cabergoline was attributed to an antiangiogenic effect through the inactivation of vascular endothelial growth factor receptor-2 (21). More than 60% of the women in both groups before treatment had experienced pelvic pain. Women who reported an increase in pain pelvic were also more likely to report dysmenorrhea, dyspareunia. In the present study, pelvic pain, dysmenorrhea, and dyspareunia significantly decreased compared with pre-treatment, and severe pelvic pain, dysmenorrhea, and dyspareunia disappeared after treatment in all patients. Also, in the present study, after three months of treatment, pelvic pain, dysmenorrhea, and dyspareunia showed a decrease in the Bromo than the placebo groups; however, this difference was not significant (Table 3). Erkayiran et al showed a reduction in the visual analog scale score for pelvic pain, dysmenorrhea, and dyspareunia after using medroxyprogesterone in women with myoma (22). Some studies have suggested that dopamine agonists such as bromocriptine, cabergoline, and quinagolide may reduce lesion size and can be used to relieve pain in women with endometriosis (9,23). Finally, our suggestions were presented for future studies on the effect of dopamine agonists in the treatment of endometriosis in a different part of the pelvis.

Limitations of the Study

Limitations of the study include a small sample size and a retrospective study design, the low accuracy in estimating endometrioma size and the relatively short follow-up, which did not allow us to draw definitive conclusions.

Conclusions

We found that medroxyprogesterone with placebo is effective in reducing the ovarian endometrioma size and also improves dysmenorrhea, dyspareunia, and pelvic pain, but the combination of medroxyprogesterone and bromocriptine has a stronger effect than using medroxyprogesterone alone.

Conflict of Interests

Authors have no conflict of interest.

Ethical Issues

The study proposal was approved by the Ethics Committee of Shiraz University of Medical Sciences, Shiraz, Iran (Code: IR.SUMS.REC.1399.979) and registered in the Iranian Registry of Clinical Trials (identifier: IRCT20140802018655N6). All participants signed a written informed consent form before entering the study.

Financial Support

Shiraz University of Medical Sciences, Shiraz, Iran financially supported this study.

Acknowledgments

The authors sincerely thank all staff of the Shiraz Ghadir Mother and Child Hospital, Shiraz, Iran for their help.

References

- Bergqvist A, Bergh T, Hogström L, Mattsson S, Nordenskjöld F, Rasmussen C. Effects of triptorelin versus placebo on the symptoms of endometriosis. *Fertil Steril*. 1998;69(4):702-708. doi:10.1016/s0015-0282(98)00019-3
- Braza-Boils A, Marí-Alexandre J, Gilabert J, et al. MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors. *Hum Reprod*. 2014;29(5):978-988. doi:10.1093/humrep/deu019
- Galczyński K, Józwiak M, Lewkowicz D, Semczuk-Sikora A, Semczuk A. Ovarian endometrioma - a possible finding in adolescent girls and young women: a mini-review. *J Ovarian Res*. 2019;12(1):104. doi:10.1186/s13048-019-0582-5
- Jiang L, Yan Y, Liu Z, Wang Y. Inflammation and endometriosis. *Front Biosci (Landmark Ed)*. 2016;21:941-948. doi:10.2741/4431
- Ashrafi M, Jahanian Sadatmahalleh S, Akhoond MR, Talebi M. Evaluation of risk factors associated with endometriosis

- in infertile women. *Int J Fertil Steril*. 2016;10(1):11-21. doi:10.22074/ijfs.2016.4763
6. Trabert B, Schwartz SM, Peters U, et al. Genetic variation in the sex hormone metabolic pathway and endometriosis risk: an evaluation of candidate genes. *Fertil Steril*. 2011;96(6):1401-1406.e3. doi:10.1016/j.fertnstert.2011.09.004
 7. Kim MK, Seong SJ, Kim YS, et al. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer. *Am J Obstet Gynecol*. 2013;209(4):358.e1-358.e4. doi:10.1016/j.ajog.2013.06.031
 8. Kim YS, Kim YJ, Kim MJ, Lee SJ, Kwon H, Lee JH. Novel medicine for endometriosis and its therapeutic effect in a mouse model. *Biomedicines*. 2020;8(12):619. doi:10.3390/biomedicines8120619
 9. Ercan CM, Kayaalp O, Cengiz M, et al. Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model. *Arch Gynecol Obstet*. 2015; 291(5):1103-1111. doi:10.1007/s00404-014-3524-x
 10. Olivares C, Ricci A, Bilotas M, Baraño RI, Meresman G. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. *Fertil Steril*. 2011;96(2):428-433. doi:10.1016/j.fertnstert.2011.05.063
 11. Novella-Maestre E, Herraiz S, Vila-Vives JM, Carda C, Ruiz-Sauri A, Pellicer A. Effect of antiangiogenic treatment on peritoneal endometriosis-associated nerve fibers. *Fertil Steril*. 2012;98(5):1209-1217. doi:10.1016/j.fertnstert.2012.07.1103
 12. Aznaurova YB, Zhumataev MB, Roberts TK, Aliper AM, Zhavoronkov AA. Molecular aspects of development and regulation of endometriosis. *Reprod Biol Endocrinol*. 2014; 12:50. doi:10.1186/1477-7827-12-50
 13. Barra F, Scala C, Mais V, Guerriero S, Ferrero S. Investigational drugs for the treatment of endometriosis, an update on recent developments. *Expert Opin Investig Drugs*. 2018;27(5):445-458. doi:10.1080/13543784.2018.1471135
 14. Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. *Expert Opin Pharmacother*. 2018;19(10):1109-1125. doi:10.1080/14656566.2018.1494154
 15. Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. *J Steroid Biochem Mol Biol*. 2002;83(1-5):149-155. doi:10.1016/s0960-0760(02)00260-1
 16. Streuli I, Gaitzsch H, Wenger JM, Petignat P. Endometriosis after menopause: physiopathology and management of an uncommon condition. *Climacteric*. 2017;20(2):138-143. doi:10.1080/13697137.2017.1284781
 17. Cosín R, Gilabert-Estellés J, Ramón LA, et al. Influence of peritoneal fluid on the expression of angiogenic and proteolytic factors in cultures of endometrial cells from women with endometriosis. *Hum Reprod*. 2010;25(2):398-405. doi:10.1093/humrep/dep419
 18. Gómez R, Abad A, Delgado F, Tamarit S, Simón C, Pellicer A. Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia. *Fertil Steril*. 2011;95(3):882-888.e881. doi:10.1016/j.fertnstert.2010.10.024
 19. Tejada M, Santos-Llamas AI, Fernández-Ramírez MJ, Tarín JJ, Cano A, Gómez R. A reassessment of the therapeutic potential of a dopamine receptor 2 agonist (D2-AG) in endometriosis by comparison against a standardized antiangiogenic treatment. *Biomedicines*. 2021;9(3):269. doi:10.3390/biomedicines9030269
 20. Hey-Cunningham AJ, Peters KM, Zevallos HB, Berbic M, Markham R, Fraser IS. Angiogenesis, lymphangiogenesis and neurogenesis in endometriosis. *Front Biosci (Elite Ed)*. 2013;5:1033-1056. doi:10.2741/e682
 21. Abdel Hamid AM, Madkour WA, Moawad A, Abd Elzaher M, Roberts MP. Does cabergoline help in decreasing endometrioma size compared to LHRH agonist? a prospective randomized study. *Arch Gynecol Obstet*. 2014;290(4):677-682. doi:10.1007/s00404-014-3242-4
 22. ErKayıran U, Köstü B, Özer A, Tok A, Karaküçük S. Levonorgestrel intrauterine device versus medroxyprogesterone acetate in treatment of symptomatic uterine fibroids. *Int J Res*. 2018;6(7):341-347. doi:10.29121/granthaalayah.v6.i7.2018.1314
 23. Pellicer N, Galliano D, Herraiz S, Bagger YZ, Arce JC, Pellicer A. Use of dopamine agonists to target angiogenesis in women with endometriosis. *Hum Reprod*. 2021;36(4):850-858. doi:10.1093/humrep/deaa337

© 2025 The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.